<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1510" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1510/" /><meta name="ncbi_pagename" content="Oculocutaneous Albinism Type 4 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Oculocutaneous Albinism Type 4 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Oculocutaneous Albinism Type 4" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/09/07" /><meta name="citation_author" content="Masahiro Hayashi" /><meta name="citation_author" content="Tamio Suzuki" /><meta name="citation_pmid" content="20301683" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1510/" /><meta name="citation_keywords" content="OCA4" /><meta name="citation_keywords" content="OCA4" /><meta name="citation_keywords" content="Membrane-associated transporter protein" /><meta name="citation_keywords" content="SLC45A2" /><meta name="citation_keywords" content="Oculocutaneous Albinism Type 4" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Oculocutaneous Albinism Type 4" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Masahiro Hayashi" /><meta name="DC.Contributor" content="Tamio Suzuki" /><meta name="DC.Date" content="2017/09/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1510/" /><meta name="description" content="Oculocutaneous albinism type 4 (OCA4) is characterized by hypopigmentation of the hair and skin plus the characteristic ocular changes found in all other types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia associated with reduction in visual acuity; and misrouting of the optic nerves at the chiasm associated with alternating strabismus, reduced stereoscopic vision, and an altered visual evoked potential (VEP). Individuals with OCA4 are usually recognized within the first year of life because of hypopigmentation of the hair and skin and the ocular features of nystagmus and strabismus. Vision is likely to be stable after early childhood. The amount of cutaneous pigmentation in OCA4 ranges from minimal to near normal. Newborns with OCA4 usually have some pigment in their hair, with color ranging from silvery white to light yellow. Hair color may darken with time, but does not vary significantly from childhood to adulthood." /><meta name="og:title" content="Oculocutaneous Albinism Type 4" /><meta name="og:type" content="book" /><meta name="og:description" content="Oculocutaneous albinism type 4 (OCA4) is characterized by hypopigmentation of the hair and skin plus the characteristic ocular changes found in all other types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia associated with reduction in visual acuity; and misrouting of the optic nerves at the chiasm associated with alternating strabismus, reduced stereoscopic vision, and an altered visual evoked potential (VEP). Individuals with OCA4 are usually recognized within the first year of life because of hypopigmentation of the hair and skin and the ocular features of nystagmus and strabismus. Vision is likely to be stable after early childhood. The amount of cutaneous pigmentation in OCA4 ranges from minimal to near normal. Newborns with OCA4 usually have some pigment in their hair, with color ranging from silvery white to light yellow. Hair color may darken with time, but does not vary significantly from childhood to adulthood." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1510/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/oca4/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1510/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BD6D1E0407D71000000000462019D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1510_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1510_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/oca2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/opmd/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1510_"><span class="title" itemprop="name">Oculocutaneous Albinism Type 4</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: OCA4</div><p class="contrib-group"><span itemprop="author">Masahiro Hayashi</span>, MD, PhD and <span itemprop="author">Tamio Suzuki</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1510_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1510_ai__"><div class="contrib half_rhythm"><span itemprop="author">Masahiro Hayashi</span>, MD, PhD<div class="affiliation small">Department of Dermatology<br />Faculty of Medicine<br />Yamagata University<br />Yamagata, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.en.ytfin@32211kzc" class="oemail">pj.en.ytfin@32211kzc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Tamio Suzuki</span>, MD, PhD<div class="affiliation small">Department of Dermatology<br />Faculty of Medicine<br />Yamagata University<br />Yamagata, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ca.u-atagamay.di.dem@zusmat" class="oemail">pj.ca.u-atagamay.di.dem@zusmat</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 17, 2005</span>; Last Update: <span itemprop="dateModified">September 7, 2017</span>.</p><p><em>Estimated reading time: 17 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="oca4.Summary" itemprop="description"><h2 id="_oca4_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Oculocutaneous albinism type 4 (OCA4) is characterized by hypopigmentation of the hair and skin plus the characteristic ocular changes found in all other types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia associated with reduction in visual acuity; and misrouting of the optic nerves at the chiasm associated with alternating strabismus, reduced stereoscopic vision, and an altered visual evoked potential (VEP). Individuals with OCA4 are usually recognized within the first year of life because of hypopigmentation of the hair and skin and the ocular features of nystagmus and strabismus. Vision is likely to be stable after early childhood. The amount of cutaneous pigmentation in OCA4 ranges from minimal to near normal. Newborns with OCA4 usually have some pigment in their hair, with color ranging from silvery white to light yellow. Hair color may darken with time, but does not vary significantly from childhood to adulthood.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of OCA4 overlaps that of the other genetic forms of albinism (oculocutaneous and ocular), the diagnosis of OCA4 is established by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> with the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC45A2</i>. A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing is the preferred molecular genetic testing method for this disorder.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Correction of refractive errors with spectacles or contact lenses to improve visual acuity. Strabismus surgery may be considered for cosmetic reasons. Dark glasses may alleviate photophobia but may reduce vision; a hat with a brim or visor best achieves reduction in photophobia. Protection from the sun, through the wearing of protective clothing and the regular application of sunscreen, is essential.</p><p><i>Prevention of secondary complications:</i> Individuals with OCA4 should stay out of the sun from an early age, because cumulative ultraviolet exposure is a major risk factor for skin cancers.</p><p><i>Surveillance:</i> Annual ophthalmologic examination and reassessment for accurate correction of refractive error. Evaluation of the skin for cancer screening every six months is recommended.</p><p><i>Agents/circumstances to avoid:</i> Prolonged exposure to sun.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>OCA4 is typically inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. The parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are obligate heterozygotes and thus carriers of one <i>SLC45A2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Heterozygotes (carriers) are asymptomatic and not at risk of developing the disorder, but may be light in pigmentation for their ethnic group. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p></div></div><div id="oca4.Diagnosis"><h2 id="_oca4_Diagnosis_">Diagnosis</h2><div id="oca4.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Oculocutaneous albinism type 4 (OCA4) <b>should be suspected</b> in individuals with the following clinical features:</p><ul><li class="half_rhythm"><div><b>Hypopigmentation</b> of the skin and hair varying from complete depigmentation to partial depigmentation with brown hair. In some individuals pigmentation increases during the first decade of life [<a class="bk_pop" href="#oca4.REF.suzuki.2008.1">Suzuki &#x00026; Tomita 2008</a>].</div></li><li class="half_rhythm"><div><b>Characteristic ocular changes</b> found in all types of albinism, including the following findings detected on routine ophthalmologic examination:</div><ul><li class="half_rhythm"><div>Nystagmus</div></li><li class="half_rhythm"><div>Reduced iris pigment with iris translucency</div></li><li class="half_rhythm"><div>Reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination</div></li><li class="half_rhythm"><div>Foveal hypoplasia associated with reduction in visual acuity</div></li></ul></li><li class="half_rhythm"><div><b>Vision abnormalities</b> (due to misrouting of the optic nerves at the chiasm) including:</div><ul><li class="half_rhythm"><div class="half_rhythm">Alternating strabismus</div></li><li class="half_rhythm"><div class="half_rhythm">Reduced stereoscopic vision</div></li><li class="half_rhythm"><div class="half_rhythm">Altered visual evoked potential (VEP)</div><div class="half_rhythm">Note: (1) A VEP is not necessary for the routine diagnosis of albinism; misrouting is implied by the finding of strabismus and reduced stereoscopic vision. (2) In some individuals, particularly those who have moderate amounts of cutaneous and retinal pigment, or those who have foveal hypoplasia and no obvious nystagmus, a VEP may be necessary to demonstrate misrouting of the optic nerves. (3) The VEP is performed with a technique specifically developed for demonstration of the misrouting and a regular VEP will not demonstrate this. (4) Normal routing of the optic nerves, demonstrated with a VEP, indicates that the diagnosis is not albinism/OCA.</div></li></ul></li></ul></div><div id="oca4.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of OCA4 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with characteristic clinical findings and/or by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC45A2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1510/table/oca4.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figoca4Tmoleculargenetictestingusedin" rid-ob="figoboca4Tmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include the use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> or <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of OCA4 overlaps that of the other genetic forms of albinism (oculocutaneous and ocular), a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or comprehensive genomic testing (when available) is the preferred <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> method for this disorder. Single-gene testing (<a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SLC45A2,</i> followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>) is rarely useful and typically NOT recommended.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SLC45A2</i> and other genes of interest associated with albinism (see <a href="#oca4.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><p>For this disorder a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that also includes <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> or <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a> is recommended if no or only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified.</p><div id="oca4.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in OCA4</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1510/table/oca4.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca4.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC45A2</i></td><td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75%-85%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_oca4.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="oca4.TF.1.1"><p class="no_margin">See <a href="/books/NBK1510/#oca4.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="oca4.TF.1.2"><p class="no_margin">See <a href="#oca4.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="oca4.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="oca4.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al [2004]</a>, <a class="bk_pop" href="#oca4.REF.sengupta.2007.1406">Sengupta et al [2007]</a>, <a class="bk_pop" href="#oca4.REF.hutton.2008.2442">Hutton &#x00026; Spritz [2008]</a>, <a class="bk_pop" href="#oca4.REF.wei.2011.124">Wei et al [2011]</a>, <a class="bk_pop" href="#oca4.REF.mauri.2017.277">Mauri et al [2017]</a></p></div></dd><dt>5. </dt><dd><div id="oca4.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="oca4.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#oca4.REF.rooryck.2008.583">Rooryck et al [2008]</a> identified <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 in <i>SLC45A2</i> in an individual who was described as having a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> at birth which became milder with age.</p></div></dd></dl></div></div></div><p>Note: <a class="bk_pop" href="#oca4.REF.oki.2017.1008">Oki et al [2017]</a> reported a multigenerational family in which OCA4 appeared to be inherited as an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition associated with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SLC45A2</i>. The authors of this <i>GeneReview</i> feel that this may represent a rare occurrence, but note that no functional assay for the specific variant was performed and that concomitant heterozygous pathogenic variant(s) in a regulatory region or in other (unknown) OCA-related genes cannot be ruled out.</p></div></div><div id="oca4.Clinical_Characteristics"><h2 id="_oca4_Clinical_Characteristics_">Clinical Characteristics</h2><div id="oca4.Clinical_Description"><h3>Clinical Description</h3><p>A wide range of clinical phenotypes has been recognized to date [<a class="bk_pop" href="#oca4.REF.suzuki.2008.1">Suzuki &#x00026; Tomita 2008</a>]. The amount of cutaneous pigmentation in OCA4 is a continuum from minimal to near normal [<a class="bk_pop" href="#oca4.REF.newton.2001.981">Newton et al 2001</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>, <a class="bk_pop" href="#oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</a>, <a class="bk_pop" href="#oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2005.385">Inagaki et al 2005</a>]. The amount of iris and retinal pigment varies and visual acuity covers a wide range; however, no subtypes of OCA4 are recognized.</p><p>Individuals with albinism (including OCA4) are usually recognized within the first year of life because of the ocular features of nystagmus and strabismus. In many families, particularly in those with darker constitutional pigmentation, the cutaneous hypopigmentation is also obvious at birth and suggests the diagnosis.</p><div id="oca4.Eye"><h4>Eye</h4><p><b>Nystagmus.</b> Some children with albinism have nystagmus that is noticed by the parents and the examining physician in the delivery room. Many children with albinism do not have nystagmus at birth and the parents note slow wandering eye movements and a lack of visual attention. The parents may become concerned because the child does not seem to "focus well," but the absence of nystagmus may delay the diagnosis. Most children with albinism develop nystagmus by age three to four months, and the diagnosis is often considered at the four-to-six month well-baby check-up. The nystagmus can be rapid early in life and generally slows with time; however, nearly all individuals with albinism have nystagmus throughout their lives. Nystagmus is more noticeable when individuals are tired, angry, or anxious, and less marked when they are well rested and feeling well [<a class="bk_pop" href="#oca4.REF.summers.2009.659">Summers 2009</a>].</p><p><b>Iris color</b> ranges from blue to brown. In one individual with OCA4, who had been misdiagnosed at birth as having OCA1 because of complete iris transillumination, the amount of iris pigment increased in the first ten years, resulting in blue iris color [<a class="bk_pop" href="#oca4.REF.suzuki.2005.174">Suzuki et al 2005</a>].</p><p><b>Visual acuity</b> in individuals with OCA4 ranges from 20/30 to 20/400 and is usually in the range of 20/100 to 20/200 [<a class="bk_pop" href="#oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</a>, <a class="bk_pop" href="#oca4.REF.suzuki.2005.174">Suzuki et al 2005</a>]. Vision is likely to be stable after early childhood and no major change or further reduction in vision should occur; loss of vision later in life is generally not related to the albinism.</p></div><div id="oca4.HairSkin"><h4>Hair/Skin</h4><p>The range of hair and skin pigment in individuals with OCA4 is broad [<a class="bk_pop" href="#oca4.REF.newton.2001.981">Newton et al 2001</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>, <a class="bk_pop" href="#oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</a>, <a class="bk_pop" href="#oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2005.385">Inagaki et al 2005</a>].</p><p><b>Hair.</b> Individuals with OCA4 are often born with some pigment in their hair that ranges in color from silvery white to light yellow.</p><ul><li class="half_rhythm"><div>Scalp hair may be very light, but it is usually not completely white (not as white as a sheet of paper or fresh snow); some parents may refer to light yellow/blond hair color as "white" or "nearly white" if it is very lightly pigmented or is much lighter than the hair color of other family members at a similar age.</div></li><li class="half_rhythm"><div>Furthermore, the definition of "white" scalp hair is not easy in some young children because the hair may be sparse and short and because some shampoos discolor hair.</div></li><li class="half_rhythm"><div>It is helpful to hold a piece of white paper next to the hair to determine if it is truly white.</div></li><li class="half_rhythm"><div>Hair color may darken with time, but usually the hair color does not change dramatically between childhood and adulthood [<a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>].</div></li></ul><p><b>Skin.</b> When hair color is blond or yellow, the skin is usually creamy white with little or no pigmentation. When hair color is somewhat darker, the skin is usually similar to that seen in unaffected individuals [<a class="bk_pop" href="#oca4.REF.thody.1991.340">Thody et al 1991</a>].</p><p>Skin color in individuals with OCA4 is not usually as white as that in individuals with the OCA1A subtype of oculocutaneous albinism type 1, reflecting the fact that skin melanocytes in individuals with OCA4 can still synthesize some melanin; however, the majority of the melanin is yellow pheomelanin rather than black-brown eumelanin.</p><p><b>Skin cancer risk.</b> Over many years, exposure of lightly pigmented skin to the sun can result in coarse, rough, thickened skin (pachydermia), solar keratoses (premalignant lesions), and skin cancer. Both basal cell carcinoma and squamous cell carcinoma can develop. The incidence rate of melanoma in individuals with OCA is unknown; however, the risk for melanoma in this population is generally considered to be higher than in unaffected individuals [<a class="bk_pop" href="#oca4.REF.streutker.2000.149">Streutker et al 2000</a>, <a class="bk_pop" href="#oca4.REF.asuquo.2009.636">Asuquo et al 2009</a>].</p><p>Skin cancer is unusual in individuals with OCA4 in the US because of the availability of sunscreens, the social acceptability of wearing clothes that cover most of the exposed skin, and the fact that individuals with albinism often do not spend a great deal of time outside in the sun. Skin cancer in an individual with any type of OCA is very rare in northern areas of the US. Skin cancer in individuals with albinism is common particularly in some parts of Africa because of the increased amount of sun exposure throughout the year, the cultural differences in protective dress, and lack of skin-protective agents such as sunscreens. In addition, African individuals with albinism tend to have poorer prognosis with skin cancer because of late presentation to care and failure to complete treatment for economic reasons [<a class="bk_pop" href="#oca4.REF.mabula.2012.5">Mabula et al 2012</a>].</p></div></div><div id="oca4.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The lack of a functional assay for the <i>SLC45A2</i> protein and the limited data from <i>SLC45A2</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> make <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> difficult [<a class="bk_pop" href="#oca4.REF.newton.2001.981">Newton et al 2001</a>, <a class="bk_pop" href="#oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</a>, <a class="bk_pop" href="#oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2005.385">Inagaki et al 2005</a>, <a class="bk_pop" href="#oca4.REF.konno.2009.1773">Konno et al 2009</a>].</p><p>Two common pathogenic alleles, <a href="#oca4.References">p.Asp157Asn</a> and <a href="#oca4.References">p.Gly188Val</a>, have been reported in Japanese individuals. The p.Asp157Asn <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> may have very low functional activity in melanogenesis; p.Gly188Val may have some residual functional activity [<a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>].</p><p>Recently, a family with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> OCA4 has been reported [<a class="bk_pop" href="#oca4.REF.oki.2017.1008">Oki et al 2017</a>], with a novel <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>: <a class="figpopup" href="/books/NBK1510/table/oca4.T.slc45a2_pathogenic_variants_discu/?report=objectonly" target="object" rid-figpopup="figoca4Tslc45a2pathogenicvariantsdiscu" rid-ob="figoboca4Tslc45a2pathogenicvariantsdiscu">c.208T&#x0003e;C</a> (p.Tyr70His). Family members with the variant demonstrate a relatively mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, with a slightly creamy complexion, brown to black hair, and mild iris hypopigmentation.</p><p>The degree of cutaneous pigmentation, ocular pigmentation, and visual development resulting from particular <i>SLC45A2</i> pathogenic variants cannot be predicted at this time.</p></div><div id="oca4.Nomenclature"><h3>Nomenclature</h3><p>The ocular features of all types of oculocutaneous albinism (OCA) and <a href="/books/n/gene/x-oa/">X-linked ocular albinism</a> (OA1) are similar and the terms "oculocutaneous albinism" and "albinism" can be used interchangeably when referring to these clinical features.</p></div><div id="oca4.Prevalence"><h3>Prevalence</h3><p>Prevalence of OCA4 is thought to be on the order of 1:100,000 in most populations throughout the world. It is likely to be more common in Japan, where it accounts for 24% of individuals with OCA [<a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2005.385">Inagaki et al 2005</a>].</p><p>OCA4 has also been described in individuals of German, Turkish, Korean, Indian, Chinese, Danish, and Moroccan descent [<a class="bk_pop" href="#oca4.REF.newton.2001.981">Newton et al 2001</a>, <a class="bk_pop" href="#oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</a>, <a class="bk_pop" href="#oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</a>, <a class="bk_pop" href="#oca4.REF.suzuki.2005.174">Suzuki et al 2005</a>, <a class="bk_pop" href="#oca4.REF.sengupta.2007.1406">Sengupta et al 2007</a>, <a class="bk_pop" href="#oca4.REF.gr_nskov.2009.1058">Gr&#x000f8;nskov et al 2009</a>, <a class="bk_pop" href="#oca4.REF.konno.2009.1773">Konno et al 2009</a>].</p></div></div><div id="oca4.Genetically_Related_Allelic_Disorde"><h2 id="_oca4_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>OCA4 is the only <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> known to be associated with pathogenic variants in <i>SLC45A2</i>.</p></div><div id="oca4.Differential_Diagnosis"><h2 id="_oca4_Differential_Diagnosis_">Differential Diagnosis</h2><div id="oca4.T.disorders_to_consider_in_the_diff" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of OCA4</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1510/table/oca4.T.disorders_to_consider_in_the_diff/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca4.T.disorders_to_consider_in_the_diff_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/OCA4</th><th headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from OCA4</th></tr></thead><tbody><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/oca1/">OCA1</a></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TYR</i></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="7" colspan="1" style="text-align:left;vertical-align:middle;">Oculocutaneous<br />albinism</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May have poorer visual acuity</td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/oca2/">OCA2</a></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>OCA2</i></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OCA3<br />(OMIM <a href="http://omim.org/entry/203290" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">203290</a>)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TYRP1</i></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Reddish hair &#x00026; freckled skin; only seen in individuals of African, Pakistani, German, Indian, &#x00026; Japanese heritage</td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OCA5<br />(OMIM <a href="http://omim.org/entry/615312" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615312</a>)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown (candidate region is on 4q24)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Golden hair</td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OCA6<br />(OMIM <a href="http://omim.org/entry/113750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">113750</a>)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC24A5</i></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Indistinguishable due to functional similarity of <i>SLC45A2</i> (OCA4) &#x00026; <i>SLC24A5</i></td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OCA7<br />(OMIM <a href="http://omim.org/entry/615179" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615179</a>)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LRMDA</i> (formerly <i>C10orf11</i>)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Relatively severe impaired visual acuity</td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hps/">Hermansky-Pudlak syndrome</a> (HPS)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HPS1</i><br /><i>AP3B1</i> (<i>HPS2</i>)<br /><i>HPS3</i><br /><i>HPS4</i><br /><i>HPS5</i><br /><i>HPS6</i><br /><i>DTNBP1</i> (<i>HPS7</i>)<br /><i>BLOC1S3</i> (<i>HPS8</i>)<br /><i>BLOC1S6</i><br /><i>AP3D1</i> (HPS10)</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Bleeding tendency, platelet dense granules; granulomatous colitis &#x00026; interstitial pneumonia in HPS1 &#x00026; HPS4; immunodeficiency &#x00026; hemophagocytic syndrome in HPS2 &#x00026; HPS10</td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/x-oa/">OA1</a></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GPR143</i></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ocular albinism</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coloring may appear normal but some may have mild hypopigmentation of skin &#x00026; hair compared to family members.</td></tr><tr><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/xl-nystag/"><i>FRMD7</i>-related infantile nystagmus</a></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FRMD7</i></td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nystagmus</td><td headers="hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_oca4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absence of oculocutaneous albinism</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd></dl></div></div></div></div><div id="oca4.Management"><h2 id="_oca4_Management_">Management</h2><div id="oca4.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with oculocutaneous albinism type 4 (OCA4), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Complete ophthalmologic evaluation including measurement of visual acuity and refractive error</div></li><li class="half_rhythm"><div>Assessment for strabismus</div></li><li class="half_rhythm"><div>Assessment by dermatologist to instruct parents regarding use of sun-protective clothing, lotions, and formulas</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="oca4.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Ophthalmologic care is the most important part of the ongoing care for most individuals with OCA4.</p><p>The majority of individuals with albinism have significant hyperopia or myopia and astigmatism. Correction of these refractive errors with spectacles or contact lenses can improve visual acuity. Except in the very unusual individual, correction of refractive errors cannot restore visual acuity to normal because of the foveal hypoplasia.</p><p>The alternating strabismus found in most individuals with albinism is generally not associated with the development of amblyopia. Strabismus surgery is usually not required, but can be considered for cosmetic reasons if the strabismus is marked or fixed.</p><p>Photophobia is common in individuals with OCA4, but the degree of discomfort varies and does not depend entirely on the amount of melanin pigment present in the iris or skin. In general, opaque contact lenses or darkly tinted lenses do not improve visual function. Dark glasses may be helpful for individuals with albinism, but many prefer to go without dark glasses because of the reduction in vision from the dark lenses. A hat with a brim (e.g., a baseball hat with a visor) is often the best way to achieve reduction in photophobia and sun protection.</p><p>Protection from the sun through the wearing of protective clothing and the regular application of sunscreen is essential to prevent sunburn and secondary skin changes, and to decrease the risk of skin cancer in later life. Regular skin check-ups for skin cancer are recommended for adult individuals with OCA4, especially in cases of severe hypopigmentation.</p></div><div id="oca4.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Individuals with OCA4 should stay out of the sun from an early age, as cumulative ultraviolet exposure is a major risk factor for skin cancers (see <a href="#oca4.HairSkin">Skin Cancer Risk</a>).</p><p>Prolonged periods in the sun require skin protection with clothing (hats with brims, long sleeves and pants, socks) and sunscreen with a high SPF number (total blocks with SPF 45-50+). There is no scientific evidence to indicate how high an SPF value is enough; individuals with OCA4 should use sunscreen with higher SPF values (45-50+) to lessen as much as possible the cumulative effect of ultraviolet to their skin.</p></div><div id="oca4.Surveillance"><h3>Surveillance</h3><p>Annual ophthalmologic examination and reassessment for accurate correction of refractive error are appropriate.</p><p>There is no definitive guideline supported by scientific evidence as to how often an individual should be evaluated by a dermatologist, though an evaluation of the skin for cancer screening every six months is recommended.</p></div><div id="oca4.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid prolonged exposure of the skin to the sun.</p></div><div id="oca4.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#oca4.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="oca4.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="oca4.Genetic_Counseling"><h2 id="_oca4_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="oca4.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>OCA4 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="oca4.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>SLC45A2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and not at risk of developing the disorder; they may be light in pigmentation for their ethnic group.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder, although they may be light in pigmentation for their ethnic group.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Unless an individual with OCA4 has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SLC45A2</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>SLC45A2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="oca4.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SLC45A2</i> pathogenic variants in the family.</p></div><div id="oca4.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="oca4.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SLC45A2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>A fetal skin biopsy will not provide an accurate diagnosis and is not appropriate for <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of OCA4.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="oca4.Resources"><h2 id="_oca4_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Albinism Database</b></div><div>University of Minnesota</div><div> MN </div><div><a href="http://www.ifpcs.org/albinism/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">albinismdb.med.umn.edu</a></div></li><li class="half_rhythm"><div><b>National Organization of Albinism and Hypopigmentation (NOAH)</b></div><div>PO Box 959</div><div>East Hampstead NH 03826-0959</div><div><b>Phone:</b> 800-473-2310 (toll-free); 603-887-2310</div><div><b>Fax:</b> 800-648-2310 (toll-free)</div><div><b>Email:</b> info@albinism.org</div><div><a href="http://www.albinism.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.albinism.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/oculocutaneous-albinism" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Oculocutaneous albinism</a></div></li><li class="half_rhythm"><div><b>PanAmerican Society for Pigment Cell Research (PASPCR)</b></div><div><a href="http://www.paspcr.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.paspcr.org</a></div></li><li class="half_rhythm"><div><b>eyeGENE - National Ophthalmic Disease Genotyping Network Registry</b></div><div><b>Phone:</b> 301-435-3032</div><div><b>Email:</b> eyeGENEinfo@nei.nih.gov</div><div><a href="https://eyegene.nih.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nei.nih.gov/eyegene</a></div></li></ul></div><div id="oca4.Molecular_Genetics"><h2 id="_oca4_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="oca4.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Oculocutaneous Albinism Type 4: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1510/table/oca4.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca4.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_oca4.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_oca4.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_oca4.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_oca4.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_oca4.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_oca4.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_oca4.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/51151" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SLC45A2</i></a></td><td headers="hd_b_oca4.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=51151" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">5p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_oca4.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UMX9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Membrane-associated transporter protein</a></td><td headers="hd_b_oca4.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.retina-international.org/files/sci-news/matpmut.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retina International Mutations of the Membrane-associated Transport Protein Gene (MATP)</a><br /><a href="http://www.ifpcs.org/albinism/oca4mut.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Albinism Database Mutations of the Membrane Associated Transporter Protein (MATP) Gene (aka SLC45A2)</a></td><td headers="hd_b_oca4.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC45A2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC45A2</a></td><td headers="hd_b_oca4.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC45A2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC45A2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="oca4.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="oca4.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Oculocutaneous Albinism Type 4 (<a href="/omim/606202,606574" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1510/table/oca4.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca4.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606202" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606202</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOLUTE CARRIER FAMILY 45, MEMBER 2; SLC45A2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606574" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606574</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALBINISM, OCULOCUTANEOUS, TYPE IV; OCA4</td></tr></tbody></table></div></div><div id="oca4.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> resulting from heterozygosity of a single <i>Slc45a2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in mice results in hypopigmentation that may be analogous to some of the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> forms of albinism reported in humans. Apparent autosomal dominant inheritance of OCA4 has been recently reported in a single Japanese family [<a class="bk_pop" href="#oca4.REF.oki.2017.1008">Oki et al 2017</a>].</p><p><b>Gene structure.</b>
<i>SLC45A2</i> has seven exons and spans 40 kb at <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 5p13.3 (<a href="/nuccore/NM_016180.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_016180.3</a>).</p><p><b>Pathogenic variants.</b> See <a href="http://albinism.med.umn.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Albinism home page</a>. Fifty-three pathogenic variants of <i>SLC45A2</i> have been reported. Most are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, but deletions of one or a small number of bases and base changes have been detected [<a class="bk_pop" href="#oca4.REF.newton.2001.981">Newton et al 2001</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>, <a class="bk_pop" href="#oca4.REF.rundshagen.2004.106">Rundshagen et al 2004</a>, <a class="bk_pop" href="#oca4.REF.ikinciogullari.2005.177">Ikinciogullari et al 2005</a>, <a class="bk_pop" href="#oca4.REF.inagaki.2005.385">Inagaki et al 2005</a>, <a class="bk_pop" href="#oca4.REF.suzuki.2005.174">Suzuki et al 2005</a>, <a class="bk_pop" href="#oca4.REF.sengupta.2007.1406">Sengupta et al 2007</a>, <a class="bk_pop" href="#oca4.REF.gr_nskov.2009.1058">Gr&#x000f8;nskov et al 2009</a>, <a class="bk_pop" href="#oca4.REF.konno.2009.1773">Konno et al 2009</a>]. The most common <i>SLC45A2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in Japanese individuals, accounting for 39% of pathogenic alleles, is the p.Asp157Asn missense variant [<a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>].</p><p>Most individuals with OCA4 are compound heterozygotes for <i>SLC45A2</i> pathogenic variants. Approximately 17% of reported Japanese individuals and a cohort from India have only one identifiable <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; the second variant could not be detected with the methods used [<a class="bk_pop" href="#oca4.REF.inagaki.2004.466">Inagaki et al 2004</a>, <a class="bk_pop" href="#oca4.REF.sengupta.2007.1406">Sengupta et al 2007</a>]. (For more information, see <a href="/books/NBK1510/#oca4.molgen.TA">Table A</a>.).</p><div id="oca4.T.slc45a2_pathogenic_variants_discu" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>SLC45A2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1510/table/oca4.T.slc45a2_pathogenic_variants_discu/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca4.T.slc45a2_pathogenic_variants_discu_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.208T&#x0003e;C</td><td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr70His</td><td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_016180.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_016180<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_057264.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_057264<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.469G&#x0003e;A</td><td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp157Asn</td></tr><tr><td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.563G&#x0003e;T</td><td headers="hd_h_oca4.T.slc45a2_pathogenic_variants_discu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly188Val</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The MATP protein consists of 530 amino acids, contains 12 transmembrane domains, and is only expressed in mealocytes (<a href="/protein/NP_057264.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_057264.3</a>) [<a class="bk_pop" href="#oca4.REF.newton.2001.981">Newton et al 2001</a>]. The precise function of the MATP protein is yet to be elucidated, although it appears to play a role in tyrosinase processing, intracellular trafficking of tyrosinase to melanosome, and regulating tyrosinase activity through controlling melanomal pH [<a class="bk_pop" href="#oca4.REF.costin.2003.3203">Costin et al 2003</a>, <a class="bk_pop" href="#oca4.REF.bin.2015.e0129273">Bin et al 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The mechanisms by which the abnormal protein alters the ability of the cell to synthesize melanin are unknown. However, tyrosinase, the rate-limiting enzyme in the biosynthesis of melanin that is associated with OCA1, appears to be mislocalized in mouse melanocytes that are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for pathogenic <i>SLC45A2</i> alleles [<a class="bk_pop" href="#oca4.REF.costin.2003.3203">Costin et al 2003</a>]. This <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is shared with melanocytes that contain pathogenic variants in <i>OCA2</i>, the gene associated with <a href="/books/n/gene/oca2/">OCA2</a> [<a class="bk_pop" href="#oca4.REF.toyofuku.2002.217">Toyofuku et al 2002</a>].</p></div></div><div id="oca4.References"><h2 id="_oca4_References_">References</h2><div id="oca4.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.asuquo.2009.636">Asuquo ME, Ngim O, Ebughe G, Bassey EE. Skin cancers amongst four Nigerian albinos. <span><span class="ref-journal">Int J Dermatol. </span>2009;<span class="ref-vol">48</span>:636–8.</span> [<a href="/pubmed/19538377" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19538377</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.bin.2015.e0129273">Bin BH, Bhin J, Yang SH, Shin M, Nam YJ, Choi DH, Shin DW, Lee AY, Hwang D, Cho EG, Lee TR. Membrane-Associated Transporter Protein (MATP) regulates melanosomal pH and influences tyrosinase activity. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0129273.</span> [<a href="/pmc/articles/PMC4461305/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4461305</span></a>] [<a href="/pubmed/26057890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26057890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.costin.2003.3203">Costin GE, Valencia JC, Vieira WD, Lamoreux ML, Hearing VJ. Tyrosinase processing and intracellular trafficking is disrupted in mouse primary melanocytes carrying the underwhite (uw) mutation. A model for oculocutaneous albinism (OCA) type 4. <span><span class="ref-journal">J Cell Sci. </span>2003;<span class="ref-vol">116</span>:3203–12.</span> [<a href="/pubmed/12829739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12829739</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.gr_nskov.2009.1058">Gr&#x000f8;nskov K, Ek J, Sand A, Scheller R, Bygum A, Brixen K, Brondum-Nielsen K, Rosenberg T. Birth prevalence and mutation spectrum in Danish patients with autosomal recessive albinism. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2009;<span class="ref-vol">50</span>:1058–64.</span> [<a href="/pubmed/19060277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19060277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.hutton.2008.2442">Hutton SM, Spritz RA. Comprehensive analysis of oculocutaneous albinism among non-Hispanic caucasians shows that OCA1 is the most prevalent OCA type. <span><span class="ref-journal">J Invest Dermatol. </span>2008;<span class="ref-vol">128</span>:2442–50.</span> [<a href="/pmc/articles/PMC3515683/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3515683</span></a>] [<a href="/pubmed/18463683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18463683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.ikinciogullari.2005.177">Ikinciogullari A, Tekin M, Dogu F, Reisli I, Tanir G, Yi Z, Garrison N, Brilliant MH, Babacan E. Meningococccal meningitis and complement component 6 deficiency associated with oculocutaneous albinism. <span><span class="ref-journal">Eur J Pediatr. </span>2005;<span class="ref-vol">164</span>:177–9.</span> [<a href="/pubmed/15565285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15565285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.inagaki.2005.385">Inagaki K, Suzuki T, Ito S, Suzuki N, Fukai K, Horiuchi T, Tanaka T, Manabe E, Tomita Y. OCA4: evidence for a founder effect for the p.D157N mutation of the MATP gene in Japanese and Korean. <span><span class="ref-journal">Pigment Cell Res. </span>2005;<span class="ref-vol">18</span>:385–8.</span> [<a href="/pubmed/16162179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16162179</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.inagaki.2004.466">Inagaki K, Suzuki T, Shimizu H, Ishii N, Umezawa Y, Tada J, Kikuchi N, Takata M, Takamori K, Kishibe M, Tanaka M, Miyamura Y, Ito S, Tomita Y. Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:466–71.</span> [<a href="/pmc/articles/PMC1182260/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1182260</span></a>] [<a href="/pubmed/14961451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14961451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.konno.2009.1773">Konno T, Abe Y, Kawaguchi M, Storm K, Biervliet M, Courtens W, Kono M, Tomita Y, Suzuki T. Oculocutaneous albinism type IV: A boy of Moroccan descent with a novel mutation in SLC45A2. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:1773–6.</span> [<a href="/pubmed/19610114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19610114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.mabula.2012.5">Mabula JB, Chalya PL, Mchembe MD, Jaka H, Giiti G, Rambau P, Masalu N, Kamugisha E, Robert S, Gilyoma JM. Skin cancers among Albinos at a university teaching hospital in Northwestern Tanzania: a retrospective review of 64 cases. <span><span class="ref-journal">BMC Dermatol. </span>2012;<span class="ref-vol">12</span>:5.</span> [<a href="/pmc/articles/PMC3483204/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3483204</span></a>] [<a href="/pubmed/22681652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22681652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.mauri.2017.277">Mauri L, Manfredini E, Del Longo A, Veniani E, Scarcello M, Terrana R, Radaelli AE, Cal&#x000f2; D, Mingoia G, Rossetti A, Marsico G, Mazza M, Gesu GP, Cristina Patrosso M, Penco S, Piozzi E, Primignani P. Clinical evaluation and molecular screening of a large consecutive series of albino patients. <span><span class="ref-journal">J Hum Genet. </span>2017;<span class="ref-vol">62</span>:277–90.</span> [<a href="/pubmed/27734839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27734839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.newton.2001.981">Newton JM, Cohen-Barak O, Hagiwara N, Gardner JM, Davisson MT, King RA, Brilliant MH. Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:981–8.</span> [<a href="/pmc/articles/PMC1274374/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1274374</span></a>] [<a href="/pubmed/11574907" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11574907</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.oki.2017.1008">Oki R, Yamada K, Nakano S, Kimoto K, Yamamoto K, Kondo H, Kubota T. A Japanese family with autosomal dominant oculocutaneous albinism type 4. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2017;<span class="ref-vol">58</span>:1008–16.</span> [<a href="/pubmed/28192564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28192564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.rooryck.2008.583">Rooryck C, Morice-Picard F, Elcioglu NH, Lacombe D, Taieb A, Arveiler B. Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects. <span><span class="ref-journal">Pigment Cell Melanoma Res. </span>2008;<span class="ref-vol">21</span>:583–7.</span> [<a href="/pubmed/18821858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18821858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.rundshagen.2004.106">Rundshagen U, Zuhlke C, Opitz S, Schwinger E, Kasmann-Kellner B. Mutations in the MATP gene in five German patients affected by oculocutaneous albinism type 4. <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">23</span>:106–10.</span> [<a href="/pubmed/14722913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14722913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.sengupta.2007.1406">Sengupta M, Chaki M, Arti N, Ray K. SLC45A2 variations in Indian oculocutaneous albinism patients. <span><span class="ref-journal">Mol Vis. </span>2007;<span class="ref-vol">13</span>:1406–11.</span> [<a href="/pubmed/17768386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17768386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.streutker.2000.149">Streutker CJ, McCready D, Jimbow K, From L. Malignant melanoma in a patient with oculocutaneous albinism. <span><span class="ref-journal">J Cutan Med Surg. </span>2000;<span class="ref-vol">4</span>:149–52.</span> [<a href="/pubmed/11003720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11003720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.summers.2009.659">Summers CG. Albinism: classification, clinical characteristics, and recent findings. <span><span class="ref-journal">Optom Vis Sci. </span>2009;<span class="ref-vol">86</span>:659–62.</span> [<a href="/pubmed/19390472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19390472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.suzuki.2005.174">Suzuki T, Inagaki K, Fukai K, Obana A, Lee ST, Tomita Y. A Korean case of oculocutaneous albinism type IV caused by a D157N mutation in the MATP gene. <span><span class="ref-journal">Br J Dermatol. </span>2005;<span class="ref-vol">152</span>:174–5.</span> [<a href="/pubmed/15656822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15656822</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.suzuki.2008.1">Suzuki T, Tomita Y. Recent advances in genetic analyses of oculocutaneous albinism types 2 and 4. <span><span class="ref-journal">J Dermatol Sci. </span>2008;<span class="ref-vol">51</span>:1–9.</span> [<a href="/pubmed/18407468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18407468</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.thody.1991.340">Thody AJ, Higgins EM, Wakamatsu K, Ito S, Burchill SA, Marks JM. Pheomelanin as well as eumelanin is present in human epidermis. <span><span class="ref-journal">J Invest Dermatol. </span>1991;<span class="ref-vol">97</span>:340–4.</span> [<a href="/pubmed/2071942" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2071942</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.toyofuku.2002.217">Toyofuku K, Valencia JC, Kushimoto T, Costin GE, Virador VM, Vieira WD, Ferrans VJ, Hearing VJ. The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase. <span><span class="ref-journal">Pigment Cell Res. </span>2002;<span class="ref-vol">15</span>:217–24.</span> [<a href="/pubmed/12028586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12028586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca4.REF.wei.2011.124">Wei A, Yang X, Lian S, Li W. Implementation of an optimized strategy for genetic testing of the Chinese patients with oculocutaneous albinism. <span><span class="ref-journal">J Dermatol Sci. </span>2011;<span class="ref-vol">62</span>:124–7.</span> [<a href="/pubmed/21458243" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21458243</span></a>]</div></li></ul></div></div><div id="oca4.Chapter_Notes"><h2 id="_oca4_Chapter_Notes_">Chapter Notes</h2><div id="oca4.Author_History"><h3>Author History</h3><p>Murray H Brilliant, PhD; University of Wisconsin School of Medicine (2005-2011)<br />Masahiro Hayashi, MD, PhD (2011-present)<br />Tamio Suzuki, MD, PhD (2011-present)</p></div><div id="oca4.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>7 September 2017 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 September 2011 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>SCL45A2</i> available clinically</div></li><li class="half_rhythm"><div>5 May 2011 (me) Comprehensive updated posted live</div></li><li class="half_rhythm"><div>14 June 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available clinically</div></li><li class="half_rhythm"><div>17 November 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>21 April 2005 (mb) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1510</span><span class="label">PMID: <a href="/pubmed/20301683" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301683</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/oca2/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/opmd/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1510&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1510/?report=reader">PubReader</a></li><li><a href="/books/NBK1510/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1510" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1510" style="display:none" title="Cite this Page"><div class="bk_tt">Hayashi M, Suzuki T. Oculocutaneous Albinism Type 4. 2005 Nov 17 [Updated 2017 Sep 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1510/pdf/Bookshelf_NBK1510.pdf">PDF version of this page</a> (427K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#oca4.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#oca4.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#oca4.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#oca4.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#oca4.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#oca4.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#oca4.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#oca4.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#oca4.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#oca4.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#oca4.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=51151[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC45A2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1493654" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1493654" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1493654" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1493654" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301410" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lewis RA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301345" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lewis RA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17980020" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous albinism.</a><span class="source">[Orphanet J Rare Dis. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous albinism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Grønskov K, Ek J, Brondum-Nielsen K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2007 Nov 2; 2:43. Epub 2007 Nov 2.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301517" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ocular Albinism, X-Linked</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ocular Albinism, X-Linked<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lewis RA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301464" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hermansky-Pudlak Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hermansky-Pudlak Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Huizing M, Malicdan MCV, Gochuico BR, Gahl WA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301683" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301683" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04127a75f66d18aaf4d42f">Oculocutaneous Albinism Type 4 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Oculocutaneous Albinism Type 4 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:52:58-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BD6D1E0407D71000000000462019D&amp;ncbi_session=CE8BD6D1E04127A1_1122SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1510%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1510&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1510/&amp;ncbi_pagename=Oculocutaneous Albinism Type 4 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BD6D1E04127A1_1122SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>